A detailed history of Ubs Group Ag transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 111,573 shares of PCVX stock, worth $9.59 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
111,573
Previous 95,676 16.62%
Holding current value
$9.59 Million
Previous $7.22 Million 76.33%
% of portfolio
0.0%
Previous 0.0%

Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$70.52 - $117.12 $1.12 Million - $1.86 Million
15,897 Added 16.62%
111,573 $12.7 Million
Q2 2024

Aug 13, 2024

SELL
$60.06 - $78.77 $4.83 Million - $6.33 Million
-80,402 Reduced 45.66%
95,676 $7.22 Million
Q1 2024

May 13, 2024

BUY
$59.79 - $81.05 $600,530 - $814,066
10,044 Added 6.05%
176,078 $12 Million
Q4 2023

Feb 09, 2024

BUY
$45.35 - $63.41 $4.16 Million - $5.82 Million
91,729 Added 123.45%
166,034 $10.4 Million
Q3 2023

Nov 09, 2023

BUY
$46.0 - $53.1 $1.31 Million - $1.51 Million
28,483 Added 62.16%
74,305 $3.79 Million
Q2 2023

Aug 11, 2023

BUY
$34.66 - $54.07 $1.58 Million - $2.46 Million
45,478 Added 13220.35%
45,822 $2.29 Million
Q1 2023

May 12, 2023

SELL
$36.27 - $47.2 $4.44 Million - $5.78 Million
-122,376 Reduced 99.72%
344 $12,000
Q4 2022

Feb 08, 2023

BUY
$20.58 - $47.95 $2.52 Million - $5.88 Million
122,645 Added 163526.67%
122,720 $5.88 Million
Q3 2022

Nov 10, 2022

SELL
$21.69 - $28.53 $509,671 - $670,397
-23,498 Reduced 99.68%
75 $2,000
Q2 2022

Aug 10, 2022

SELL
$17.68 - $26.58 $650,871 - $978,516
-36,814 Reduced 60.96%
23,573 $513,000
Q1 2022

May 16, 2022

BUY
$17.46 - $26.36 $264,553 - $399,406
15,152 Added 33.5%
60,387 $1.46 Million
Q4 2021

Feb 14, 2022

SELL
$19.32 - $26.45 $1.48 Million - $2.02 Million
-76,552 Reduced 62.86%
45,235 $1.08 Million
Q3 2021

Nov 15, 2021

BUY
$20.26 - $26.97 $281,289 - $374,451
13,884 Added 12.87%
121,787 $3.09 Million
Q2 2021

Aug 13, 2021

SELL
$16.45 - $24.06 $124,148 - $181,580
-7,547 Reduced 6.54%
107,903 $2.43 Million
Q1 2021

May 12, 2021

BUY
$18.66 - $29.16 $882,319 - $1.38 Million
47,284 Added 69.37%
115,450 $2.28 Million
Q4 2020

Feb 11, 2021

BUY
$26.57 - $51.74 $1.79 Million - $3.49 Million
67,446 Added 9367.5%
68,166 $1.81 Million
Q3 2020

Nov 12, 2020

BUY
$26.5 - $55.4 $19,080 - $39,888
720 New
720 $36,000

Others Institutions Holding PCVX

About Vaxcyte, Inc.


  • Ticker PCVX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,315,100
  • Market Cap $5.1B
  • Description
  • Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...
More about PCVX
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.